Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High - Risk NMIBC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02365818
What this trial is testing

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

Who this might be right for
Bladder Cancer
CG Oncology, Inc. 66
Early research (Phase 1)Study completedNCT05085977
What this trial is testing

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT03504163
What this trial is testing

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Who this might be right for
Bladder Cancer
Memorial Sloan Kettering Cancer Center 45
Testing effectiveness (Phase 2)UnknownNCT05957757
What this trial is testing

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20
Large-scale testing (Phase 3)Active Not RecruitingNCT06211764
What this trial is testing

TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Who this might be right for
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC 272
Testing effectiveness (Phase 2)Study completedNCT04498702
What this trial is testing

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

Who this might be right for
Non-muscle Invasive Bladder Cancer
Jiangsu Yahong Meditech Co., Ltd aka Asieris 41
Early research (Phase 1)Active Not RecruitingNCT06181266
What this trial is testing

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Who this might be right for
NMIBCHigh Risk NMIBCNon Muscle Invasive Bladder Cancer
Prokarium Ltd 22
Testing effectiveness (Phase 2)Study completedNCT04172675
What this trial is testing

Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 107
Testing effectiveness (Phase 2)Looking for participantsNCT05943379
What this trial is testing

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Who this might be right for
NMIBC
RemeGen Co., Ltd. 85
Testing effectiveness (Phase 2)Study completedNCT03636256
What this trial is testing

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaUrinary Bladder Neoplasm+6 more
NanOlogy, LLC 36
Early research (Phase 1)UnknownNCT04134000
What this trial is testing

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Who this might be right for
Invasive Bladder Cancer
Fundacion Oncosur 40
Testing effectiveness (Phase 2)Study completedNCT04387461
What this trial is testing

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder Cancer
CG Oncology, Inc. 35
Early research (Phase 1)UnknownNCT06427291
What this trial is testing

Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients

Who this might be right for
Bladder Cancer
Fudan University 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07777848
What this trial is testing

Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).

Who this might be right for
Non-muscle Invasive Bladder Cancer (NMIBC)
Ractigen Therapeutics. 114
Testing effectiveness (Phase 2)Ended earlyNCT03519256
What this trial is testing

Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Who this might be right for
Urinary Bladder Neoplasms
Bristol-Myers Squibb 142
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06255964
What this trial is testing

IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
SUNHO（China）BioPharmaceutical CO., Ltd. 236
Not applicableStudy completedNCT07798479
What this trial is testing

Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study

Who this might be right for
Bladder CancerNMIBC
Insel Gruppe AG, University Hospital Bern 64
Large-scale testing (Phase 3)Looking for participantsNCT06696794
What this trial is testing

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang 180
Early research (Phase 1)Study completedNCT03191578
What this trial is testing

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®

Who this might be right for
High-Risk Non-Muscle-Invasive Bladder Cancer
Archivel Farma S.L. 44
Not applicableLooking for participantsNCT07036731
What this trial is testing

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Who this might be right for
Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University 428
Next Page